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Abstract In women with hereditary non polyposis colo-
rectal carcinoma (HNPCC) an annual gynaecological sur-
veillance has been recommended because of an increased
lifetime risk of developing endometrial and ovarian carci-
noma. The aim of this study was to assess the efﬁcacy of
gynaecological surveillance with regard to endometrial and
ovarian carcinoma. Included were women from families
that fulﬁlled the revised Amsterdam criteria for HNPCC or
who showed a proven mutation in one of the mismatch
repair genes. An annual gynaecological surveillance was
performed (transvaginal ultrasound (TVU) and CA 125
assessment). From January 2006 on, routine endometrial
sampling was included. In a total number of 100 women
285 surveillance visits were performed. Among these, in 64
visits routine endometrial samplings were performed: three
atypical hyperplasias and one endometrial carcinoma were
diagnosed. This was signiﬁcantly more than the atypical
hyperplasia and two endometrial carcinomas that were
detected after 28 samples performed because of abnormal
surveillance results in 221 visits. There were no interval
carcinomas. One invasive ovarian carcinoma stage IIIC
was diagnosed at ovarian surveillance. Endometrial sur-
veillance with routine endometrial sampling in women
with HNPCC is more efﬁcient in diagnosing endometrial
(pre)malignancies than TVU only. Ovarian surveillance is
not capable of diagnosing early stage ovarian carcinoma.
Prophylactic hysterectomy in HNPCC should be restricted
to women in whom abdominal surgery for other reasons is
performed and to those with particularly increased risk
such as MSH6 mutation carriers and/or women with mul-
tiple relatives with endometrial carcinoma.
Keywords Endometrial carcinoma  Endometrial
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Abbreviations
HNPCC Hereditary non polyposis colorectal
carcinoma
TVU Transvaginal ultrasound
MMR gene Mismatch repair gene
BSO Bilateral salpingo-oophorectomy
LNG-IUS Levonorgestrel releasing intrauterine
system
CA 125 Cancer antigen 125
BRCA gene Breast cancer gene
Introduction
Lynch syndrome is an autosomal dominantly inherited dis-
order characterized by a marked increase in carcinoma sus-
ceptibility caused by a germline mutation in one of the
mismatch repair (MMR) genes, which are MLH1, MSH2,
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Familial Cancer (2009) 8:391–397
DOI 10.1007/s10689-009-9252-xMSH6 and PMS2 [1, 2]. Hereditary non polyposis colorectal
carcinoma (HNPCC) is deﬁned as positive revised Amster-
damCriteria[3]and/oraprovedmutationinoneoftheMMR
genes. Next to an enhanced lifetime risk for colorectal car-
cinoma (18–73%), women with HNPCC have an increased
lifetime risk to develop endometrial and ovarian carcinoma,
being 27–70% and 3–28%, respectively [4, 5]. MSH 2
mutation carriers seem to be at higher risk for endometrial
carcinomathanMLH1carriers,andMSH6carriersmaybeat
even greater risk up to 70% [6, 7].
For women with HNPCC current surveillance protocols
recommend annual transvaginal ultrasound (TVU) and
determination of tumor markers such as CA 125 [2, 8].
Whether either endometrial surveillance or prophylactic
hysterectomy is optimal in terms of beneﬁts and risks is
still subject of debate. This gives major implications for
risk management counselling. Good quantiﬁcation of the
diagnostic accuracy of endometrial surveillance in daily
practice is needed, as prophylactic surgery is irreversible.
There is conﬂicting evidence as far as the efﬁcacy of
endometrial surveillance with TVU in women with
HNPCC is concerned. One study found three pre-malig-
nancies and one interval endometrial carcinoma [2].
Another study failed to demonstrate any clinical beneﬁt of
the surveillance with TVU and also found two interval
endometrial carcinomas, diagnosed at an early stage [8].
The lack of evidence of endometrial surveillance with
TVU combined with the favourable prognosis for endo-
metrial carcinoma patients, questioned the need for sur-
veillance. However, in a recent study by Renkonen et al.
endometrial carcinoma surveillance appeared to be highly
effective with the addition of endometrial sampling.
Moreover, the tumors that were identiﬁed at routine
endometrial sampling were smaller and tended to be at an
earlier stage compared to the symptomatic cases [9].
A large retrospective study in women with Lynch syn-
drome suggested that prophylactic hysterectomy and
bilateral salpingo-oophorectomy (BSO) might be effective
strategies. Serious complications such as postoperative
infection or bleeding do occur but are rare [4, 10]. It might
be suggested that after hysterectomy colonoscopy may be
more painful compared to women who did not have a
hysterectomy [11]. Considering the mean life time risk of
6–8% on ovarian carcinoma in women with HNPCC there
is neither evidence nor consensus as to whether this risk is
high enough to perform prophylactic surgery.
The aim of the present study was to evaluate the efﬁcacy
of annual gynaecological surveillance in women with
HNPCC with regard to endometrial and ovarian carcinoma
at the Family Cancer Clinic at the tertiary referral centre of
the Radboud University Nijmegen Medical Centre, The
Netherlands.
Materials and methods
Study population
All female members with either colorectal carcinoma (or
another HNPCC related carcinoma) or who are ﬁrst degree
member of a cancer patient in families with HNPCC, who
visited the Family Cancer Clinic of the Radboud University
Nijmegen Medical Centre with the uterus (and/or adnexa)
in situ were referred for annual gynaecological surveillance
to the department of gynaecological oncology. The Family
Cancer Clinic is a multidisciplinary team of clinicians,
including a clinical geneticist, a gastroenterologist, a sur-
geon, a medical oncologist and a gynaecological oncologist
with weekly meetings where all different aspects of the
medical policy of patients with HNPCC are discussed.
Data used for this analysis were collected from January
1997 till February 2008. Primary surveillance was started
from the age of 30 or 5 years before the ﬁrst family
member was diagnosed with endometrial or ovarian car-
cinoma. Women under the age of 30 were offered one
single surveillance visit with general information to return
for annual surveillance after their 30th anniversary. When
during the surveillance program a mutation was found in a
family all included family members who appeared to be no
carrier of the mutation were excluded from the surveillance
program.
At primary surveillance information on age of menar-
che, use of oral contraceptives, parity, medical history,
occurrence of cancer in the family, mutation test results
and the pre-and post-menopausal status were collected. All
patients with abnormal ﬁndings at surveillance and/or other
important issues (such as prophylactic surgery) were dis-
cussed at the weekly meeting.
Surveillance
Surveillance visits were performed annually and consisted
of pelvic examination, TVU and measurement of serum
CA 125 levels. Women were asked to report clinical
symptoms. Before 2006 endometrial sampling (micro
curettage in the outpatient clinic) was only indicated in
case of postmenopausal/irregular bleeding and/or abnormal
ﬁndings at TVU: in postmenopausal women when the TVU
showed irregularity, polyps or endometrial thickness more
than 4 mm and in premenopausal women when there was
an endometrial thickness of more than 12 mm preovula-
tory, an irregularity/polyp or when the ultrasound was not
well assessable. In January 2006 routine endometrial
sampling was added to the surveillance. When microcu-
rettage was technically impossible or when insufﬁcient
material was obtained, hysteroscopy and/or curettage were
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123performed to obtain representative endometrial tissue. In
case of a (pre)malignancy of the uterus hysterectomy
and BSO was advised. The cut-off value for CA 125 was
35 U/ml. With respect to the ovaries, in case of an
abnormal pelvic examination and/or TVU and/or CA 125,
revision after 3 months was advised, unless ﬁndings were
highly suspicious for a malignancy in which case the
patient was asked to return earlier for follow-up or diag-
nostic surgery such as laparoscopy.
Prophylactic surgery
At primary counselling patients were informed on the
advantage (possible earlier diagnosis of (pre)malignancy)
and disadvantages of surveillance (no prevention of carci-
noma and the risk of false positive ﬁndings resulting in a
higher rate of diagnostic surgery). Patients were informed
that prophylactic surgery was not the standard of care in
our institute, unless the patient needed abdominal surgery
for other reasons e.g. colorectal carcinoma. In case the
patient nevertheless opted for prophylactic surgery this was
discussed in the multidisciplinary team of the family cancer
clinic.
In case ofsurgeryfor prophylactic ortherapeutic reasons,
all removed specimens such as uterus, ovaries and tubes
were separately examined by an experienced gynaecologic
pathologist. After hysterectomy and BSO women were dis-
missed from further surveillance. In case of surgery with
savingtheuterusand/oroneortwoovaries,patientsreturned
to the surveillance program.
Results
Patient characteristics
A total number of 100 women fulﬁlled the inclusion cri-
teria from January 1997 till February 2008 and were
enrolled in our surveillance program.
The median age of the women was 46 years (range 23–
72 years). In 12 women the mutation status was not (yet)
known because they were in the procedure of testing
(n = 5) or the patient refused DNA analysis (n = 7). Five
patients were tested negative for the MMR-gene mutation
known to be present in their family and were dismissed
from further surveillance. In another 16 patients (and their
families) DNA analysis did not reveal a mutation; however,
they preferred surveillance because the family fulﬁls the
revised Amsterdam criteria [3]. An overview of the patient
characteristics is given in Table 1. Six women underwent
prophylactic surgery: one BSO (with a hysterectomy in the
past) because the patient preferred BSO above surveillance
and discontinued surveillance afterwards; two patients
opted nevertheless for prophylactic hysterectomy with
BSO and three women developed colorectal carcinoma and
preferred after counselling prophylactic hysterectomy and
BSO in the same operation session.
Endometrial surveillance
A total number of 100 women underwent 285 surveillance
visits till February 2008. In seven patients hysterectomy
and BSO was performed due to endometrial (pre)malig-
nancies. Since January 2006 49 routine endometrial sam-
plings and 15 hysteroscopies and/or curettages in 64
surveillance visits diagnosed three patients with atypical
hyperplasia and one patient with endometrial carcinoma
(endometrial carcinoma stage IB in patient with MSH 6
mutation; curettage showed atypical hyperplasia while
deﬁnitive histopathology showed invasive disease). The
(pre)malignancies were found in 6.3% of the visits which
was signiﬁcantly higher (P = 0.026) compared to the
period of 8 years before the introduction of routine endo-
metrial sampling: 17 microcurettages and 15 hysteroscop-
ies and/or curettages had been performed because of
abnormal TVU and/or complaints in 221 surveillance vis-
its. The three (pre)malignities found concerned 1.4% of the
surveillance visits. One patient was diagnosed with atypical
hyperplasia and two patients with endometrial carcinomas.
One endometrial carcinoma patient with MSH2 mutation
had irregular bleeding at the ﬁrst visit, which appeared to
be stage IIIC disease (prevalent case) and the other patient
with MLH1 mutation had an abnormal endometrial
Table 1 Patient characteristics of study population (100 women) at
primary surveillance
Median age
Median follow-up
Median number of visits
46 years (range 23–72 years)
1 year (range 0–16 years)
1 (range 1–16)
Number of patients
Type mutation
MLH1 22
MSH2 22
MSH6 23
No mutation found 16
Tested, no results yet or unknown 5
Tested negative during
surveillance
(family positive)
5
Unknown (not tested) 7
Menopausal state
Premenopausal 72
Postmenopausal 22
Unknown 6
Improvement of endometrial biopsy 393
123thickness of 8 mm at her third surveillance visit. There
were no interval carcinomas. See Table 2 for an overview
of the seven patients who underwent surgery for their
endometrial (pre)malignancies (four hyperplasia with aty-
pia and three endometrial carcinomas).
Ovarian surveillance
In 100 patients, 12 interval surveillance visits and three CT
scans were performed due to suspicious ovaries with TVU
or raise of serum CA 125. Eight surgeries were performed:
one hysterectomy with BSO, two BSO, one SO, three
laparoscopic explorations and one abdominal exploration
with debulking. The ﬁnal pathological result showed nor-
mal ovaries in ﬁve patients, one borderline malignancy and
one mature teratoma; one patient with MSH2 mutation
appeared to have stage IIIC ovarian carcinoma. For an
overview of these patients see Table 3.
Surveillance results
The median number of surveillance visits per patient was 1
(range 1–16) and the median follow-up was 1 year (range
0–15) in a total of 286 women-years. The average follow-
up was 2.8 years (See Table 1). Table 4 gives an overview
of the results of the different surveillance tools.
At the time of this analysis, 54 women still participate in
thesurveillanceprogram.Oftheother46women,17women
had undergone hysterectomy with BSO (six because of
prophylactic reasons or because of colorectal carcinoma
surgery), seven women underwent surveillance somewhere
else, 12 women were lost for follow-up, ﬁve patients
appeared to be a non carrier, four patients were advised to
start screening after their 30th birthday and one patient
(temporary) stopped surveillance on their own initiative.
Duringsurveillanceonepatientdiedfromovariancarcinoma
and two women died from colorectal carcinoma. No women
died from endometrial carcinoma. The patients with endo-
metrial carcinoma were, respectively, 8, 11 and 21 months
aftertheirdiagnosisanddidnotshowanysignofrecurrence.
Discussion
In women with HNPCC asymptomatic endometrial
(pre)malignancies can be identiﬁed by annual endometrial
surveillance, which preferably includes routine endometrial
sampling than TVU alone. Based on these results, combined
with data from literature, we conclude that endometrial
carcinoma surveillance in women with HNPCC could be
effective and therefore the medical indications for prophy-
lactic hysterectomy should be restricted [9].
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123In our study we identiﬁed in total seven patients
with endometrial (pre)malignancies: adding of routine
endometrial sampling led to the diagnosis endometrial
(pre)malignancy in four of these cases, which is in 6.3% of
64 visits. The other (pre)malignancies were found in 221
visits where specimens were collected because of abnormal
surveillance results (1.4%). From our data there is no good
correlation between endometrial thickness and (pre)malig-
nant pathology. This emphasizes that it is unknown whether
endometrial carcinoma in women with HNPCC always
arises through the (pre)malignant precursor hyperplasia.
Our results are in concordance with the ﬁndings by Ren-
konen et al. who analysed the role of routine endometrial
sampling and showed an increase in ﬁnding (pre)malig-
nancies at an earlier stage, like we did. Endometrial sam-
pling can be performed without sedation at the outpatient
clinic and has similar sensitivity as dilatation and curettage
in detecting endometrial abnormalities [9, 12, 13]. We did
not ﬁnd any interval carcinoma, possibly due to a limited
follow-up which is a defect in our study.
Currently results of surveillance may be improved by a
better selection of women at risk, e.g. by selecting only
MMR-gene mutation carriers. A substantial part of our
patients were members of HNPCC families without an
established mutation. Microsatellite instability (MSI) of
tumor DNA is a hallmark of the presence of MMR dys-
function. Currently MSI investigation of the tumor is a
helpful tool to identify families that are prone to a MMR
gene mutation. When MSI analysis in the most suspected
carcinoma of the family turns out to be MSI-negative the
diagnosis of Lynch syndrome is unlikely and in most cases
such families will be excluded from further endometrial
surveillance [14].
Prophylactic surgery can be an option for prevention of
gynaecological malignancies in women with HNPCC. A
study by Schmeler et al. provides strong evidence that
uterine and ovarian carcinomas can be prevented in women
with Lynch syndrome by prophylactic surgery. They found
that patients who underwent hysterectomy did not develop
endometrial carcinoma, whereas patients who did not
undergo hysterectomy, endometrial carcinoma did occur.
Similar ﬁndings were reported for ovarian carcinoma and
BSO in patients with Lynch syndrome [4, 15]. The removal
of the uterus and adnexa (by vaginal, abdominal or lapa-
roscopic procedure) may cause infection, bleeding, ureter/
bladder and bowel injuries, but these complications are rare
[16]. After hysterectomy, colonoscopy may be more difﬁ-
cult and painful and is associated with a reduction of polyp
detection rate [11]. Another issue is the good prognosis in
case endometrial carcinoma is detected, because it can
mostly be treated with hysterectomy and BSO. At the
moment the 5-years survival for women with HNPCC with
endometrial carcinoma is more than 80% [17]. It is
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123unlikely we could achieve a better prognosis by a sur-
veillance program.
In the future, another alternative for patients with endo-
metrial hyperplasia orearlyendometrial carcinomacouldbe
a levonorgestrel releasing intrauterine system (LNG-IUS)
with frequent endometrial sampling. A recent promising
small study has shown that LNG-IUS can provide reduction
of endometrial hyperplasia and early stage endometrial
carcinoma; however, the evidence is limited [18]. An inter-
national study on the topic has started in the UK.
In the general population there is evidence that oral
contraceptives decrease the incidence of both ovarian and
endometrial carcinoma. Oral contraceptives might also
decrease carcinoma risk in patients with Lynch syndrome,
but there is lack of data in these women [19].
Regarding the risk of ovarian carcinoma in HNPCC
mutation carriers, surveillance of the ovaries is disputable.
Nevertheless, we included surveillance of the ovaries in our
program. In our study one patient without complaints was
diagnosed with advanced ovarian carcinoma based on TVU
and CA 125 and she died within 5 months after diagnosis.
Surveillance for ovarian carcinoma in BRCA mutations
carriers has proven to be inefﬁcient, while these women
have an even higher lifetime risk for developing ovarian
carcinoma as compared to women with HNPCC [20].
Considering the mean lifetime risk of 6–8% on ovarian
carcinoma in women with HNPCC there is neither evi-
dence nor consensus as to whether this risk is high enough
to perform prophylactic surgery.
Hysterectomy with BSO is discussed with a HNPCC
patients who will undergo abdominal surgery for other
reasons e.g. colorectal carcinoma as well as in women with
an MSH6 mutation and/or multiple relatives with endo-
metrial carcinoma. For decision making in the treatment of
women with HNPCC with respect to prophylactic surgery
we wanted to point out the necessity of multidisciplinary
Table 4 Results of surveillance tools and interventions
Surveillance tool or
diagnostic intervention
Number of
patients
Outcome
TVU 285 240 Normal
23 Ovarian abnormality ? cyst 12 additional consults ? 8 surgeries:
1 ? ovarian carcinoma
a
1 ? mature teratoma
1 ? borderline malignancy
5 ? normal ovaries
22 Endometrial abnormality
12 ? endometrial thickness increased
5 ? polyp
5 ? myoma
? Microcurettage/hysteroscopy with biopsy
or curettage
CA 125 (U/ml) 270 265 B35
5 [35 ? 316 ? also enlarged ovary ? ovarian
carcinoma
a
? 162,6 ? also enlarged ovary ? exploration:
borderline malignancy
? 81 ? repeat of measurement: same
outcome ? exploration ? normal anatomy
? 42,4 ? exploration ? normal anatomy
? 51,0 ? exploration ? normal anatomy
Microcurettage/curettage/biopsy
taken as routine (after January
2006)
64 49 Normal
11 Inadequate material Further analysis as possible
b
4 Abnormal 3 ? hyperplasia with atypia
1 ? endometrial carcinoma
Microcurettage/curettage/biopsy
taken after complaints
or abnormal TVU (before
Jan 2006)
32 24 Normal
5 Inadequate material Further analysis as possible
b
3 Abnormal 1 ? hyperplasia with atypia
2 ? endometrial carcinoma
a Same patient with ovarian cancer: enlarged ovary and elevated CA 125
b Return to surveillance for in total two patients without ﬁnal pathological diagnosis, but low clinical suspicion
396 L. H. M. Gerritzen et al.
123teams of clinicians, including a clinical geneticist, a gas-
troenterologist, a surgeon, a medical oncologist and a
gynaecological oncologist. It is necessary to be informed
by the gastroenterologist whether an optimal colonoscopy
is possible when a hysterectomy is planned and vice versa.
This will also provide the possibility of combined surgeries
between surgical and gynaecological specialties, reducing
morbidity in patients [21].
In conclusion, gynaecological surveillance with TVU
and CA 125 is efﬁcient for endometrial carcinoma (and
will even be improved by routine endometrial sampling)
but not for ovarian carcinoma. A multidisciplinary setting
will further optimise the care and decision making in
women with HNPCC. In women with HNPCC we rec-
ommend further studies to investigate the prevention of
endometrial carcinoma by levonorgestrel releasing intra
uterine system and the role of prophylactic surgery.
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